Venkatraman Seshan, PhD

Director of Biostatistics Computer-Intensive Support Services

Office Phone




Stanford University

Current Research Interests

Dr. Seshan’s current research interests are in the area of methods for the analysis of high throughput data, specifically from genomic profiling such as DNA copy number and methylation arrays.  He developed with Adam Olshen the CBS algorithm for the analysis of DNA copy number data and has extended the method to allele copy number estimation.  He is collaborating with Drs. Begg, Olshen and Ostrovnaya on extending these methods to distinguish second cancers from metastases.  He is responsible for the research computing environment for the members of the department.


Cannan-Kuhl S, Venkatraman E, Ernst SIB, Olshen RA, Myers BD. Relationships among protein and albumin concentrations and oncotic pressure in nephrotic plasma. Amer J Physiol: Renal, Fluid and Electrolyte Physiology 1993; 33:F1052-1059.

Garber AM, Olshen RA, Zhang H, Venkatraman E. Predicting high-risk cholesterol. Int Stat Rev 1994; Rev 62:203-228.

Rusch V, Saltz L, Venkatraman E, Ginsburg R, McCormack P, Burt M, Markman M, Kelsen D. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994; 12:1156-1163.

Miller VA, Rigas JR, Muindi JRF, Tong WP, Venkatraman E, Kris MG, Warrell RP. Modulation of All-Trans retinoic acid pharmacokinetics by Liarozole. Cancer Chemoth Pharm 1994; 34:522-526.

Siegmund DO, Venkatraman E. Using the generalized likelihood ratio statistic for sequential detection of a change-point. Ann Stat 1995; 23:255-271.

Read more

  1. Miller VA, Rigas JR, Francis PA, Venkatraman ES, Houlihan N, Hanna T, Woolley K, Heelan RT, Kris MG. Phase II trial of a 75 mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995;75:968-972.

  2. Curtin JP, Saigo P, Slucher B, Venkatraman ES, Mychalczak B, Hoskins W. Soft tissue sarcoma of the vagina and vulva: A clinicopathologic study. Obstet Gynecol 1995; 86:269-272.

  3. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, Dmitrovsky E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995;55:5038-5042.

  4. Gibson LE, Barakat RR, Venkatraman ES, Hoskins WJ. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers. Cancer J Sci Am. 1996; 2:35-8.

  5. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996; 111:815-826.

  6. Curtin JP, Hoskins WJ, Venkatraman ES, Almadrones L, Podratz KC, Long H, Teneriello M, Averette H, Sevin B. Adjuvant chemotherapy vs chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy. Gynecol Oncol 1996; 61:3-10.

  7. Welshinger M, Finstad CL, Venkatraman E, Federici MG, Rubin SC, Lewis Jr. JL, Lloyd KO. Expression of A-Blood-Group, B-Blood-Group, and H-Blood-Group antigens in epithelial ovarian-cancer-relationship to tumor grade and patient survival. Gynecol Oncol 1996; 62:106-112.

  8. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 1996; 62:798-809.

  9. Abu-Rustum NR, Barakat RR, Siegel PL, Venkatraman ES, Curtin JP, Hoskins WJ. Second-look operation for epithelial ovarian cancer: laparoscopy or laparotomy? Obstet Gynecol 1996; 88:549-553.

  10. Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD. Are more antiemetic trials with a placebo necessary? Cancer 1996; 78:2193-2198.

  11. Heller G, Venkatraman ES. A bootstrap procedure to compare two survival distributions in the presence of right censored data. Biometrics 1996; 52:1204-1213.

  12. Venkatraman ES, Begg CB. A distribution-free procedure for comparing receiver operating characteristic curves from a paired experiment. Biometrika 1996; 83:835-848.

  13. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: Impact of surgical debulking. Gynecol Oncol 1997; 64:9-12.

  14. Barakat RR, Fennelly D, Pizzuto F, Venkatraman ES, Brown C, Curtin JP. Salvage intraperitoneal therapy of advanced epithelial ovarian-cancer - impact of retroperitoneal nodal disease. Eur J Gynaecol Oncol 1997; 18:161-163.

  15. Abu-Rustum NR, Barakat RR, Venkatraman E, Spriggs D. Chemotherapy and total parenteral-nutrition for advanced ovarian-cancer with bowel obstruction. Gynecol Oncol 1997; 64:493-495.

  16. Rusch V, Klimstra D, Venkatraman E, Pisters PWT, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor á is frequent in resectable non-small cell lung cancer but does not predict tumor progression.1 Clin Cancer Res 1997; 3:515-522.

  17. Abu-Rustum NR, Aghanjanian CA, Venkatraman ES, Feroz F, Barakat RR. Metastatic breast-carcinoma to the abdomen and pelvis. Gynecol Oncol 1997; 66:41-44.

  18. Chi DS, Fong Y, Venkatraman ES, Barakat RR. Hepatic resection for metastatic gynecologic carcinomas. Gynecol Oncol 1997; 66:45-51.

  19. Finstad CL, Lloyd KO, Federici MG, Divgi C, Venkatraman ES, Barakat RR, Finn RD, Larson SM, Hoskins WJ, Humm JL. Distribution of radiolabeled monoclonalantibody MX35 F(AB1)2 in tissue samples by storage phosphor screen image-analysis- evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer. Clin Cancer Res 1997; 8:1433-1442.

  20. Shapiro F, Schneider J, Markman M, Reichman BS, Venkatraman E, Barakat R, Almadrones, Spriggs D. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: A pilot trial with ten-year follow-up. Gynecol Oncol 1997; 67:39-45.

  21. Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol Oncol 1997; 67:56-60.

  22. Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, Klimstra D, Venkatraman E, Moore MA, Dmitrovsky E. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 1997; 89:1609-1615.

  23. Korst RJ, Rush VW, Venkatraman E, Bains MS, Burt ME, Downey RJ, Ginsberg RJ. Proposed revision of the staging classification for esophageal cancer. J Thor Surg1998; 115:660-669.

  24. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998; 58:1120-3.

  25. Barakat RR, Almadrones L, Venkatraman ES, Aghajanian C, Brown C, Shapiro F, Curtin JP, Spriggs D. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian-cancer following negative surgical assessment. Gynecol Oncol 1998; 69:17-22.

  26. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatraman ES, Reuter VE, Fair WR, Ling CC, Fuks Z. Dose-escalation with 3-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Rad Onc 1998; 41:491-500.

  27. Aghajanian C, Fennelly D, Shapiro F, Waltzman R, Almadrones L, O’Flaherty C, O’Conner K, Venkatraman E, Barakat R, Curtin J, Brown C, Reich L, Wuest D, Norton L, Hoskins W, Spriggs DR. Phase II study of “dose-dense” high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998; 16(5):1852-60.

  28. Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher HI. A new parameter for measuring metastatic bone involvement by prostate-cancer - the bone scan index. Clin Cancer Res 1998; 4:1765-1772.

  29. Yao TJ, Venkatraman ES. Optimal two-stage design for a series of pilot trials of new agents. Biometrics 1998; 54:1183-1189.

  30. Zelefsky MJ, Fuks Z, Wolfe T, Kutcher GJ, Burma C, Ling CC, Venkatraman ES, Leibel SA. Locally advanced prostatic-cancer - long-term toxicity outcome after 3-dimensional conformal radiation-therapy - a dose-escalation study. Radiology 1998; 209:169-174.

  31. Gemignani ML, Curtin JP, Zelmanovich J, Patel A, Venkatraman E, Barakat RR. Laparoscopic-assisted vaginal hysterectomy for endometrial cancer: clinical outcomes and hospital charges. Gynecol Oncol 1999; 73:5-11.

  32. Husain A, Sabbatini P, Spriggs D, Fennelly D, Aghajanian C, Barakat R, Curtin J, Venkatraman E, Hoskins, Markman M. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer. Gynecol Oncol 1999;73:96-101.

  33. Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatraman ES, Leibel SA. Long-term tolerance of high-dose 3-dimensions conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999; 85:2460-2468.

  34. Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 1999; 5:301-306.

  35. Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 1999; 75:99-102.

  36. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999; 68:1799-1804.

  37. Venkatraman ES, Begg CB. Properties of a nonparametric test for early comparison of treatments in clinical trials in the presence of surrogate endpoints. Biometrics 1999; 55:1171-1176.

  38. Downey RJ, Rusch V, Hsu FI, Leon L, Venkatraman ES, Linehan D, BainsM, vanZee K, Korst R, Ginsberg R. Chest wall resection for locally recurrent breast cancer: is it worthwhile? J Thorac Cardiovasc Surg 2000; 119:420-428.

  39. Skwarchuk MW, Jackson A, Zelefsky MJ, Venkatraman ES, Cowen DM, Levegrun S, Burman CM, Fuks Z, Leibel SA, Ling CC. Late rectal toxicity after conformal radiotherapy of prostate-cancer (I) - multivariate-analysis and dose-response. Int J Rad Oncol 2000; 47:103-113.

  40. Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000; 77:227-231.

  41. Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, Hunt M, Wolfe T, Venkatraman ES, Jackson A, Skwarchuk M, Leibel SA. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000; 55:241-249.

  42. Rusch VW, Parekh KR, Leon L, Venkatraman E, Bains MS, Downey RJ, Boland P, Bilsky M, Ginsberg RJ. Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. J Thorac Surg 2000; 119:1147-1153.

  43. Levegrun S, Jackson A, Zelefsky MJ, Venkatraman ES, Skwarchuk MW, Schlegel W, Fuks Z, Leibel SA, Ling CC. Analysis of biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer using dose-distribution variables and tumor control probability models. Int J Radiat Oncol Biol Phys 2000; 47:1245-1260.

  44. Begg CB, Cramer LD, Venkatraman ES, Rosai J. Comparing tumor staging and grading systems: a case study and a review of the issues, using thymoma as a model. Stat Med 2000; 19:1997-2014.

  45. Zelefsky MJ, Yamada Y, Cohen G, Venkatraman ES, Fung AYC, Furhang E, Silvern D, Zaider M. Postimplantation dosimetric analysis of permanent transperineal prostate implantation - improved dose distributions with an intra operative computer optimized conformal planning technique. Int J Radiat Oncol 2000; 48:601-608.

  46. Gemignani ML, Cody HS, Fey JV, Tran KN, Venkatraman E, Borgen PI. Impact of sentinel lymph-node mapping on relative charges in patients with early-stage breast cancer. Ann Surg Oncol 2000; 7:575-580.

  47. Makhija S, Sabbatini P, Aghajanian C, Venkatraman E, Spriggs DR, Barakat R. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive 2nd look. Gynecol Oncol 2000; 79:28-32.

  48. Barakat RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, Hudis C, Hoskins WJ. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer - a prospective study using office endometrial biopsy. J Clin Oncol 2000;18:3459-3463.

  49. Venkatraman ES. A permutation test to compare receiver operating characteristic curves. Biometrics 2000; 56:1134-1138.

  50. Gemignani ML, Hensley ML, Cohen R, Venkatraman ES, Saigo PE, Barakat RR. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol 2001; 80:16-20.

  51. Jackson A, Skwarchuk MW, Zelefsky MJ, Cowen DM, Venkatraman ES, Levegrun S, Burman CM, Kutcher GJ, Fuks Z, Liebel SA. Late rectal bleeding after conformal radiotherapy of prostate cancer (II) - volume effects and dose-volume histograms. Int J Rad Oncol 2001; 49:685-698.

  52. Hensley ML, Lebeau D, Leon LF, Venkatraman E, Waltzman R, Sabbatini P, Almadrones L, Chi D, Spriggs D. Identification of risk-factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Gynecol Oncol 2001; 81:485-489.

  53. Gemignani ML, Alektiar KM, Leitao M, Mychalczak B, Chi D, Venkatraman E, Barakat RR, Curtin JP. Radical surgical resection and high-dose intraoperative radiation-therapy (HDR-IORT) in patients with recurrent gynecologic cancers. Int J Rad Oncol 2001; 50:687-694.

  54. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA. High-dose radiation delivered by intensity-modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166:876-881.

  55. Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001; 82:532-537.

  56. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, Bains MS, Downey RJ, Ginsberg RJ. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Surg 2001;122:788-795.

  57. Martin J, Ginsberg RJ, Abolhoda A, Bains MS, Downey RJ, Korst RJ, Weigel TL, Kris MG, Venkatraman ES, Rusch VW. Morbidity and mortality after neoadjuvant therapy for lung cancer - the risks of right pneumonectomy. Ann Thorac Surg 2001;72:1149-1154.

  58. Kolesnick R, Fuks Z, Venkatraman E. Endothelial-cells and radiation gastrointestinal syndrome - response (editorial). Science 2001; 294:1411.

  59. Levegrun S, Jackson A, Zelefsky MJ, Skwarchuk MW, Venkatraman ES, Schlegel W, Fuks Z, Leibel SA, Ling CC. Fitting tumor control probability models to biopsy outcome after 3 dimensional conformal radiation therapy of prostate cancer - pitfalls in deducing radiobiological parameters for tumors from clinical data. Int J Rad Oncol 2001; 51:1064-1080.

  60. Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, Aghajanian C, Hensley M, Soignet S, Brown C. Intraperitoneal chemotherapy for ovarian carcinoma - results of long term follow-up. J Clin Oncol 2002; 20:694-698.

  61. Padula GDA, Zelefsky MJ, Venkatraman ES, Fuks Z, Lee HJ, Natle L, Leibel SA. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal-therapy and 3 dimensional conformal radiotherapy for prostate cancer. Int J Rad Oncol 2002; 52:439-443.

  62. Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E, Spriggs D. Retropsective analysis of carboplatin and paclitaxel as initial 2nd line therapy for recurrent epithelial ovarian carcinoma - application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002; 20:1238-1247.

  63. Satagopan JM, Verbel DA, Venkatraman ES, Offit KE, Begg CB. Two-stage designs for gene-disease association. Biometrics 2002; 58:163-170.

  64. Levegrun S, Jackson A, Zelefsky MJ, Venkatraman ES, Skwarchuk MW, Schlegel W, Fuks Z, Leibel SA, Ling CC. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol 2002; 63:11-26.

  65. Martin J, Ginsberg RJ, Venkatraman ES, Bains MS, Downey RJ, Korst RJ, Kris MG, Rusch VW. Long term results of combined modality therapy in resectable non-small cell lung cancer. J Clin Oncol 2002; 20:1989-1995.

  66. Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, Chi D, Bergman A, Hricak H. Peritoneal metastases - detection with spiral CT in patients with ovarian cancer. Radiology 2002; 223:495-499.

  67. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-2831.

  68. Osman I, Sherman E, Singh B, Venkatraman E, Zelefsky M, Bosl G, Scher H, Shah J, Shaha A, Kraus D. Alteration of p53 pathway in squamous-cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 2002; 20:2980-2987.

  69. Alektiar KM, McKee A, Venkatraman ES, McKee B, Zelefsky MJ, Mychalczak BR, Hoskins WJ, Barakat RR. Intravaginal high-dose-rate brachytherapy for Stage 1B (FIGO Grade 1, 2) endometrial cancer. Intl J Rad Oncol 2002; 53:707-713.

  70. Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, Mychalczak BR, Mc- Kee B, Hoskins WJ, Barakat RR. The significance of the amount of myometrial invasion in patients with stage IB endometrial carcinoma. Cancer 2002; 95:316-321.

  71. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA. High dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Intl J Rad Oncol 2002;53:1111-1116.

  72. Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, McKee B, Hoskins WJ, Barakat RR. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid figo grade 3 cancer. Int J Rad Oncol 2002; 54:79-85.

  73. Yorke ED, Jackson A, Rosenzweig KE, Merrick SA, Gabrys D, Venkatraman ES, Burman CM, Leibel SA, Ling CC. Dose volume factors contributing to the incidence of radiation pneumonitis in non-small cell lung cancer patients treated with 3-dimensional conformal radiation therapy. Int J Rad Oncol 2002; 54:329-339.

  74. Pothuri B, Chi DS, Reid T, Aghajanian C, Venkatraman E, Alektiar K, Bilsky M, Barakat RR. Craniotomy for central nervous system metastases in epithelial ovarian carcinoma. Gynecol Oncol 2002; 87:133-137.

  75. Ebright MI, Zakowski MF, Martin J, Venkatraman ES, Miller VA, Bains MS, Downey RJ, Korst RJ, Kris MG, Rusch VW. Clinical-pattern and pathological stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002; 74:1640-1647.

  76. Leitao MM, Brennan MF, Hensley M, Sonoda Y, Hummer A, Haskaran D, Venkatraman E, Alektiar K, Barakat RR. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol 2002; 87:287-294.

  77. Krug LM, Miller VA, Filippa DA, Venkatraman E, Ng KK, Kris MG. Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine. Lung Cancer 2003; 39:139-43.

  78. Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003; 21:483-489.

  79. Pothuri B, Ramondetta L, Martino M, Alektiar K, Eifel PJ, Deavers MT, Venkatraman E, Soslow RA, Barakata RR. Development of endometrial cancer after radiation treatment for cervical carcinoma. Obstet Gynecol 2003; 101:941-945.

  80. Pothuri B, Vaidya A, Aghajanian C, Venkatraman E, Barakat RR, Chi DS. Palliative surgery for bowel obstruction in recurrent ovarian-cancer - an updated series. Gynecol Oncol 2003; 89:306-313.

  81. Krug LM, Azzoli CG, Kris MG, Miller VA, Khokhar NZ, Tong W, Ginsberg MS, Venkatraman E, Tyson L, Pizzo B, Baez V, Ng KK, Sirotnak FM. 10 propargyl-10 deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res 2003; 9:2072-2078.

  82. Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E, Boyd J. Rose of KRAS and BRAF gene-mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003; 90:378-381.

  83. Eitan R, Gemignani ML, Venkatraman ES, Barakat KK, Aburustum NR. Breast cancer metastatic to abdomen and pelvis. Role of surgical resection. Gynecol Oncol 2003; 90:397-401.

  84. Aburustum NR, Sonoda Y, Chi DS, Teoman H, Dizon DS, Venkatraman E, Barakat RR. The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. Gynecol Oncol 2003; 90:431-434.

  85. Maj JG, Paris F, Haimovitz-Friedman A, Venkatraman E, Kolesnick R, Fuks Z. Microvascular function regulates intestinal crypt response to radiation. Cancer Res 2003; 63:4338-4341.

  86. Leitao MM Jr, Hummer A, Dizon DS, Aghajanian C, Hensley M, Sabbatini P, Venkatraman E, Springgs DR. Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 2003; 91:123-129.

  87. Lucito R, Healy J, Alexander J, Reiner A, Esposito D, Chi M, Rodgers L, Brady A, Sebat J, Troge J, West JA, Rostan S, Nguyen KC, Powers S, Ye KQ, Olshen A, Venkatraman E, Norton L, Wigler M. Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res 2003; 13:2291-2305.

  88. Yamada Y, Potters L, Zaider M, Cohen G, Venkatraman E, Zelefsky MJ. Impact of intraoperative edema during transperineal permanent prostate brachytherapy on computer-optimized and preimplant planning techniques. Am J Clin Oncol 2003; 26:130-135.

  89. Aburustum NR, Gemignani ML, Moore K, Sonoda Y, Venkatraman E, Brown C, Poynor E, Chi DS, Barakat RR. Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator - pilot data and comparison to laporotomy. Gynecol Oncol 2003; 91:402-409.

  90. Alektiar KM, Venkatraman E, Aburustum, Barakat RR. Is endometrial carcinoma intrinsically more aggressive in elderly patients. Cancer 2003; 98:2368-2377.

  91. Venkatraman ES, Mitra N, Begg CB. A method for evaluating the impact of individual haplotypes on disease incidence in molecular epidemiology studies. Stat Appl Genet Mol Biol. 2004; 3:Article27.

  92. Leitao MM Jr, Boyd J, Hummer A, Olvera N, Arroyo CD, Venkatraman E, Baergen RN, Dizon DS, Barakat RR, Soslow RA. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol 2004; 28:147-59.

  93. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, RuschV, Heelan RT. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-1109.

  94. Stier E, Freeman-Wang T, Hochberg L, Hummer A, Venkatraman E,Walker P. Using the cone biopsy to compare colposcopy clinics in New York and London. J Low Genit Tract Dis 2004; 8(2):106-111.

  95. Sherman EJ, Rubin DM, Venkatraman E, Schwartz GK, Miller VA, Radzyner MH, Ruchlin HS, Spriggs D, Pfister DG. Using patients as their own controls for cost evaluation of phase I clinical trials. J Clin Oncol 2004; 22:1308-1314.

  96. Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, Dizon D, O’Flaherty C, Bloss J, Chi D, Spriggs D. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. Clin Cancer Res 2004; 10:2962-2967.

  97. Hong L, Alektiar KM, Hunt M, Venkatraman E, Leibel SA. Intensity-modulated radiotherapy for soft tissue sarcoma of the thigh. Int J Radiat Oncol Biol Phys 2004; 59:752-759.

  98. Pao W, Miller VA, Venkatraman E, Kris MG. Predicting sensitivity of non-small cell lung cancer to gefitinib: is there a role for P-Akt? J Natl Cancer Inst 2004; 96:1117-1119.

  99. Satagopan JM, Venkatraman ES, Begg CB. Two-stage designs for gene-disease association studies with sample size constraints. Biometrics 2004; 60:589-597.

  100. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004; 5:557-572.

  101. Chi DS, Abu-Rustum NR, Sonoda Y, Awtrey C, Hummer A, Venkatraman ES, Franklin CC, Hamilton F, Gemignani ML, Barakat RR. Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. Am J Obstet Gynecol 2004; 191:1138-1145.

  102. Rengan R, Rosenzweig KE, Venkatraman E, Koutcher LA, Fox JL, Nayak R, Amols H, Yorke E, Jackson A, Ling CC, Leibel SA. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 60:741-747.

  103. Sarkaria IS, Pham D, Ghossein RA, Talbot SG, Hezel M, Dudas ME, Ebright MI, Chuai S, Memoli N, Venkatraman ES, Miller VA, Kris MG, Zakowski MF, Rusch VW, Singh B. SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma. Ann Thorac Surg 2004; 78:1734-1741.

  104. Heller G, Venkatraman ES. A nonparametric test to compare survival distributions with covariate adjustment. JRSS-B 2004; 66:719-733.

  105. Eitan R, Saenz CC, Venkatraman ES, Hann L, Bach A, Gretz E, Barakat RR, Chi DS. Pilot study prospectively evaluating the use of the measurement of preoperative sonographic endometrial thickness in postmenopausal patients with endometrial cancer. Menopause 2005; 12:27-30.

  106. Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Leibel SA, Venkatraman ES. Outcome predictors for the increasing PSA state after definitive external beam radiotherapy for prostate cancer. J Clin Oncol 2005; 23:826-831.

  107. Alektiar KM, Venkatraman E, Chi DS, Barakat RR. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2005;62:111-117.

  108. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, Micciche F, Ricci R, Morganti AG, Gambacorta MA, Maurizi F, Coco C. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005; 62:752-760.

  109. Krug LM, Miller VA, Patel J, Crapanzano J, Azzoli CG, Gomez J, Kris MG, Heelan RT, Pizzo B, Tyson L, Sheehan C, Ross JS, Venkatraman E. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Cancer 2005; 104(10):2149-55.

  110. Dupont J, Aghajanian C, Andrea G, Lovegren M, Chuai S, Venkatraman E, Hensley M, Anderson S, Spriggs D, Sabbatini P. Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important? Int J Gynecol Cancer 2006; 16 Suppl 1:68-73.

  111. Weyant MJ, Bains MS, Venkatraman E, Downey RJ, Park BJ, Flores RM, Rizk N, Rusch VW. Results of chest wall resection and reconstruction with and without rigid prosthesis. Ann Thorac Surg. 2006; 81(1):279-85.

  112. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(3 Pt 1):839-44.

  113. Mourton SM, Chi DS, Sonoda Y, Alektiar KM, Venkatraman ES, Barakat RR, Abu-Rustum NR. Mesorectal lymph node involvement and prognostic implications at total pelvic exenteration for gynecologic malignancies. Gynecol Oncol 2006; 100(3):533-6.

  114. Chen W, Houldsworth J, Olshen AB, Nanjangud G, Chaganti S, Venkatraman ES, Halaas J, Teruya-Feldstein J, Zelenetz AD, Chaganti RS. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood 2006; 107(6):2477-85.

  115. Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S, Venkatraman ES, Miller VA, Ladanyi M, Pao W, Wilson RK, Singh B, Rusch VW. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006; 24(11):1700-4.

  116. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006; 1(4):289-95.

  117. Loganathan RS, Stover DE, Shi W, Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 2006;129(5):1305-12.

  118. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, Venkatraman ES, Aghajanian C, Sonoda Y, Abu-Rustum NR, Barakat RR. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106(9):1933-9.

  119. McCreath WA, Eisenhauer EL, Abu-Rustum NR, Venkatraman ES, Caceres A, Bier R, Huh J, Cho J, Barakat RR, Chi DS. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma. Gynecol Oncol 2006; 102(1):8-14.

  120. Hensley ML, Correa DD, Thaler H, Wilton A, Venkatraman E, Sabbatini P, Chi DS, Dupont J, Spriggs D, Aghajanian C. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol Oncol 2006; 102(2):270-7.

  121. Milton DT, Azzoli CG, Heelan RT, Venkatraman E, Gomez JE, Kris MG, Krug LM,Pao W, Rizvi NA, Dunne M, Miller VA. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 2006;107(5):1034-41.

  122. Zelefsky MJ, Ben-Porat L, Chan HM, Fearn PA, Venkatraman ES. Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66(2):382-8.

  123. Lee NY, de Arruda FF, Puri DR, Wolden SL, Narayana A, Mechalakos J, Venkatraman ES, Kraus D, Shaha A, Shah JP, Pfister DG, Zelefsky MJ. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 66(4):966-74.

  124. Rizk N, Venkatraman E, Park B, Flores R, Bains MS, Rusch V; American Joint Committee on Cancer staging system. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2006;132(6):1374-81.

  125. Moskovitz AH, Rizk NP, Venkatraman E, Bains MS, Flores RM, Park BJ, Rusch VW. Mortality increases for octogenarians undergoing esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2006; 82(6):2031-6; discussion 2036.

  126. Rizk NP, Venkatraman E, Bains MS, Park B, Flores R, Tang L, Ilson DH, Minsky BD, Rusch VW; American Joint Committee on Cancer. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007; 25(5):507-12.

  127. Leiser AL, Maluf FC, Chi DS, Sabbatini P, Hensley ML, Schwartz L, Venkatraman E, Spriggs D, Aghajanian C. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. Int J Gynecol Cancer 2007; 17(2):379-86.

  128. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007; 23(6):657-63.

  129. Krug LM, Heelan RT, Kris MG, Venkatraman E, Sirotnak FM. Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol 2007; 2(4):317-20.

  130. Fury MG, Zahalsky A, Wong R, Venkatraman E, Lis E, Hann L, Aliff T, Gerald W, Fleisher M, Pfister DG. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 2007; 25(2):165-72.

  131. Panageas KS, Schrag D, Russell Localio A, Venkatraman ES, Begg CB. Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. Stat Med 2007; 26(9):2017-35.

  132. Azzoli CG, Krug LM, Gomez J, Miller VA, Kris MG, Ginsberg MS, Henry R, Jones J, Tyson L, Dunne M, Pizzo B, Farmer A, Venkatraman E, Steffen R, Sirotnak FM. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clin Cancer Res 2007; 13(9):2692-8.

  133. Antczak C, Shum D, Escobar S, Bassit B, Kim E, Seshan VE, Nian Wu, Guangli Yang, Ouerfelli O, Li YM, Scheinberg DA, Djaballah H. High-throughput identification of inhibitors of human mitochondrial Peptide deformylase. J Biomol Screen 2007;12(4):521-35.

  134. Azzoli CG, Krug LM, Miller VA, Rizvi NA, Kris MG, Dunne M, Farmer A, Pizzo B, Tyson L, Seeger T, Coleman B, Moore E, Lastinger L, Venkatraman E, Rudin CM. A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer. J Thorac Oncol 2007; 2(7):638-44.

  135. Lee N, Chan K, Bekelman JE, Zhung J, Mechalakos J, Narayana A, Wolden S, Venkatraman ES, Pfister D, Kraus D, Shah J, Zelefsky MJ. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 68(3):731-40.

  136. Hensley ML, Dizon D, Derosa F, Venkatraman E, Sabbatini P, Chi DS, Dupont J, Colevas AD, Spriggs D, Aghajanian C. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs 2007;25(4):335-41.

  137. Harrison ML, Gore ME, Spriggs D, Kaye S, Iasonos A, Hensley M, Aghajanian C, Venkatraman E, Sabbatini P. Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials. Gynecol Oncol 2007; 106(3):469-75.

  138. Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, Lee C, Yeoh C, Bains M, Rusch V. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007; 2(10):957-65.

  139. Alam N, Park BJ, Wilton A, Seshan VE, Bains MS, Downey RJ, Flores RM, Rizk N, Rusch VW, Amar D. Incidence and risk factors for lung injury after lung cancer resection. Ann Thorac Surg 2007; 84(4):1085-91.

  140. Huang J, Rizk NP, Travis WD, Seshan VE, Bains MS, Dycoco J, Downey RJ, Flores RM, Park BJ, Rusch VW. Abstract Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg. 2007;134(6):1477-83; discussion 1483-4.

  141. Rizk NP, Seshan VE, Bains MS, Ilson DH, Minsky BD, Tang L, Rusch VW. Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol. 2007 2(12):1117-23.

  142. Sarkaria IS, Zakowski MF, Pham D, Hezel M, Ebright MI, Chuai S, Venkatraman ES, Kris MG, Rusch VW, Singh B. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components. Ann Thorac Surg. 2008 85(1):216-23.

  143. Cattaneo SM, Park BJ, Wilton AS, Seshan VE, Bains MS, Downey RJ, Flores RM, Rizk N, Rusch VW. Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. Ann Thorac Surg. 2008 85(1):231-5; discussion 235-6.

  144. Wen B, Urano M, Humm JL, Seshan VE, Li GC, Ling CC. Comparison of Helzel and OxyLite Systems in the Measurements of Tumor Partial Oxygen Pressure (pO(2)). Radiat Res. 2008 169(1):67-75.

  145. Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, Ladanyi M, Pao W. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008 3(2):111-6.

  146. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. J Thorac Cardiovasc Surg. 2008 135(3):620-626.

  147. Moskowitz CS, Seshan VE, Riedel ER, Begg CB. Estimating the empirical Lorenz curve and Gini coefficient in the presence of error with nested data. Stat Med. 2008 27(16):3191-208.

  148. Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, Johnson J, Zatcky J, Zelefsky MJ, Fuks Z. High-Dose, Single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008 71(2):484-90.

  149. Ostrovnaya I, Seshan VE, Begg CB. Comparison of properties of tests for assessing tumor clonality. Biometrics. 2008 64(4):1018-22.

  150. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, Gerald WL, Travis WD. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008 32(6):810-27.

  151. Wright JD, Seshan VE, Shah M, Schiff PB, Burke WM, Cohen CJ, Herzog TJ. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008 199(5):536.e1-8.

  152. Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, Wright JD. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol. 2008 112(1):64-70.

  153. Kriminski SA, Lovelock DM, Seshan VE, Ali I, Munro P, Amols HI, Fuks Z, Bilsky M, Yamada Y. Comparison of kilovoltage cone-beam computed tomography with megavoltage projection pairs for paraspinal radiosurgery patient alignment and position verification. Int J Radiat Oncol Biol Phys. 2008 71(5):1572-80.

  154. Shum D, Radu C, Kim E, Cajuste M, Shao Y, Seshan VE, Djaballah H. A high density assay format for the detection of novel cytotoxic agents in large chemical libraries. J Enzyme Inhib Med Chem. 2008 23(6):931-45.

  155. Director’s Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine 2008 14(8):822-7.

  156. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008 455(7216):1061-8.

  157. Flores RM, Routledge T, Seshan VE, Dycoco J, Zakowski M, Hirth Y, Rusch VW. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2008 136(3):605-10.

  158. Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials 2008 5(5):465-77.

  159. Wethington SL, Herzog TJ, Seshan VE, Bansal N, Schiff PB, Burke WM, Cohen CJ, Wright JD. Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer. 2008 113(12):3298-306.

  160. Huang W, Li X, Morris EA, Tudorica LA, Seshan VE, Rooney WD, Tagge I, Wang Y, Xu J, Springer CS Jr. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. Proc Natl Acad Sci U S A. 2008 105(46):17943-17948.

  161. Li X, Huang W, Morris EA, Tudorica LA, Seshan VE, Rooney WD, Tagge I, Wang Y, Xu J, Springer CS Jr. Dynamic NMR effects in breast cancer dynamic-contrast enhanced MRI. Proc Natl Acad Sci U S A. 2008 105(46):17937-17942.

  162. Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Sirotnak FM, Seshan VE, Fogle M, Ginsberg M, Miller VA, Rudin CM. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol. 2009 27(2):264-70.

  163. Antczak C, Shum D, Radu C, Seshan VE, Djaballah H. Development and validation of a high-density fluorescence polarization-based assay for the trypanosoma RNA triphosphatase TbCet1. Comb Chem High Throughput Screen. 2009 Mar;12(3):258-68.

  164. Ferguson SE, Malhotra T, Seshan VE, Levine DA, Sonoda Y, Chi DS, Barakat RR, Abu-Rustum NR. A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery. Gynecol Oncol. 2009 Jul;114(1):111-6. Epub 2009 Apr 23.

  165. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Seshan VE, Zakowski MF, Rusch V, Pao W, Gerald W, Ladanyi M. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene. 2009 Aug 6;28(31):2773-83. Epub 2009 Jun 15.

  166. Paoluzzi L, Scotto L, Marchi E, Seshan VE, O’Connor OA. The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor. Br J Haematol. 2009 Sep;146(6):656-9. Epub 2009 Jul 8.

  167. O’Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, Neylon E, Mastrella J, Hamelers R, Macgregor-Cortelli B, Patterson M, Seshan VE, Sirotnak F, Fleisher M, Mould DR, Saunders M, Zelenetz AD. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009 Sep 10;27(26):4357-64. Epub 2009 Aug 3.

  168. Zelefsky MJ, Shi W, Yamada Y, Kollmeier MA, Cox B, Park J, Seshan VE. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1350-6. Epub 2009 Jun 8.

  169. Khokhar S, Mironov S, Seshan VE, Stover DE, Khirbat R, Feinstein M. Antibiotic Use in the Management of Pulmonary Nodules. Chest. 2010 Feb;137(2):369-75. Epub 2009 Sep 25.

  170. Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O’Connor OA. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res. 2010 Jan 15;16(2):554-65. Epub 2010 Jan 12.

  171. Finley DJ, Yoshizawa A, Travis W, Zhou Q, Seshan VE, Bains MS, Flores RM, Rizk N, Rusch VW, Park BJ. Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol. 2010 Feb;5(2):197-205.

  172. Ostrovnaya I, Olshen AB, Seshan VE, Orlow I, Albertson DG, Begg CB. A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data. Stat Med. 2010 Jul 10;29(15):1608-21.

  173. Marchi E, Paoluzzi L, Scotto L, Seshan VE, Zain JM, Zinzani PL, O’Connor OA. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res. 2010 Jul 15;16(14):3648-58. Epub 2010 May.\

  174. Phillips AA, Shapira I, Willim RD, Sanmugarajah J, Solomon WB, Horwitz SM, Savage DG, Bhagat G, Soff G, Zain JM, Alobeid B, Seshan VE, O’Connor OA. A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer. 2010 Jul 15;116(14):3438-46.

  175. Montanari F, O’Connor OA, Savage DG, Zain JM, Venkatraman S, McCormick EK, Crook MT, Tsao L, Sevilla DW, Bhagat G, Alobeid B. Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors. Hum Pathol. 2010 Aug;41(8):1150-8. Epub 2010 Apr 8.

  176. Montanari F, Bhagat G, Clark-Garvey S, Seshan V, Zain J, Diefenbach C, McCormick E, Crook M, Conroy M, O’Connor OA. Monomorphic T-cell post-transplant lymphoproliferative disorders exhibit markedly inferior outcomes compared to monomorphic B-cell post-transplant lymphoproliferative disorders. Leuk Lymphoma. 2010 Sep;51(9):1761-4.